Mylan shares soar on Amazon reports, FDA approvals

The U.S. Food and Drug Administration approved both Mylan NV ’s generic blood thinner and breast and stomach cancer treatment. But that may not be the only reason that Mylan’s (Nasdaq:MYL) stock was up more than 5 percent by 2:30 p.m. Friday. The generic drug sector as a whole was boosted by a CNBC report that Amazon is in preliminary talks with Mylan and Novartis about the Seattle-based tech giant entering the pharmaceuticals space. Mylan, whose executive team is based in Canonsburg, did…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news